ID

43909

Descrição

An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy; ODM derived from: https://clinicaltrials.gov/show/NCT00162201

Link

https://clinicaltrials.gov/show/NCT00162201

Palavras-chave

Versões (2)
  1. 11/12/2016 11/12/2016 -
  2. 20/09/2021 20/09/2021 -
Transferido a

20 de setembro de 2021

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Rheumatoid Arthritis NCT00162201

Inglês

Eligibility Rheumatoid Arthritis NCT00162201

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
ra for at least 1 year
Descrição

Rheumatoid Arthritis disease length

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0872146
clear clinical signs of active ra in 1 knee joint
Descrição

Rheumatoid Arthritis Knee joint Clinical signs

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0022745
UMLS CUI [1,3]
C3540840
meet ara (1987) criteria for diagnosis of ra and acr (1991) criteria for ra functional classes i, ii, or iii
Descrição

Rheumatoid Arthritis Class Functional

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0456387
UMLS CUI [1,3]
C0205245
inadequate clinical response to a minimum of 3 months of therapy with anti-tnf-blocking agents
Descrição

Tumor necrosis factor alpha (TNF-) inhibitors Duration of therapy | Clinical Response Inadequate

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3653350
UMLS CUI [1,2]
C0444921
UMLS CUI [2,1]
C4055223
UMLS CUI [2,2]
C0205412
taking background dmards for a minimum of 3 months and at stable doses for at least 28 days
Descrição

Disease-Modifying Antirheumatic Drugs Background | Duration of therapy Dose Stable

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0242708
UMLS CUI [1,2]
C1706907
UMLS CUI [2,1]
C0444921
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205360
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
serious bacterial infection in last 3 months
Descrição

Bacterial Infection Serious

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0004623
UMLS CUI [1,2]
C0205404
history of tb
Descrição

Tuberculosis

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0041296
history of cancer within 5 years
Descrição

Malignant Neoplasms

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0006826
evidence of latent or active bacterial or viral infection
Descrição

Bacterial Infection Latent Evidence of | Bacterial Infection Evidence of | Virus Disease Latent Evidence of | Virus Disease Evidence of

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0004623
UMLS CUI [1,2]
C0205275
UMLS CUI [1,3]
C0332120
UMLS CUI [2,1]
C0004623
UMLS CUI [2,2]
C0332120
UMLS CUI [3,1]
C0042769
UMLS CUI [3,2]
C0205275
UMLS CUI [3,3]
C0332120
UMLS CUI [4,1]
C0042769
UMLS CUI [4,2]
C0332120
intra-articular corticosteroids within 3 months
Descrição

intraarticular injection of corticosteroids

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2064783
exposure to live vaccines
Descrição

Exposure to Attenuated Vaccines

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C0042211
exposure to ctla4ig or bms-188667
Descrição

Exposure to abatacept | Exposure to BMS 188667

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0332157
UMLS CUI [1,2]
C1619966
UMLS CUI [2,1]
C0332157
UMLS CUI [2,2]
C0378942
treatment with immunoadsorption column(s), mycophenolate mofetil, leflunomide, anakinra, cyclosporine, etanercept, adalimumab, infliximab, azathioprine, oral or parenteral gold, d-penacillamine, calcineurin inhibitors, cyclophosphamide or other alkylating agents
Descrição

Apheresis Immunoadsorption Columns | mycophenolate mofetil | leflunomide | anakinra | Cyclosporine | Etanercept | adalimumab | infliximab | Azathioprine | Oral form medicinal gold | Parenteral form medicinal gold | Penicillamine | Calcineurin inhibitor | Cyclophosphamide | Alkylating Agents

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0179100
UMLS CUI [2]
C0209368
UMLS CUI [3]
C0063041
UMLS CUI [4]
C0245109
UMLS CUI [5]
C0010592
UMLS CUI [6]
C0717758
UMLS CUI [7]
C1122087
UMLS CUI [8]
C0666743
UMLS CUI [9]
C0004482
UMLS CUI [10]
C2585247
UMLS CUI [11]
C2585314
UMLS CUI [12]
C0030817
UMLS CUI [13]
C1562036
UMLS CUI [14]
C0010583
UMLS CUI [15]
C0002073
Voltar ao início da página

Similar models

Eligibility Rheumatoid Arthritis NCT00162201

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis disease length
Item
ra for at least 1 year
boolean
C0003873 (UMLS CUI [1,1])
C0872146 (UMLS CUI [1,2])
Rheumatoid Arthritis Knee joint Clinical signs
Item
clear clinical signs of active ra in 1 knee joint
boolean
C0003873 (UMLS CUI [1,1])
C0022745 (UMLS CUI [1,2])
C3540840 (UMLS CUI [1,3])
Rheumatoid Arthritis Class Functional
Item
meet ara (1987) criteria for diagnosis of ra and acr (1991) criteria for ra functional classes i, ii, or iii
boolean
C0003873 (UMLS CUI [1,1])
C0456387 (UMLS CUI [1,2])
C0205245 (UMLS CUI [1,3])
Tumor necrosis factor alpha (TNF-) inhibitors Duration of therapy | Clinical Response Inadequate
Item
inadequate clinical response to a minimum of 3 months of therapy with anti-tnf-blocking agents
boolean
C3653350 (UMLS CUI [1,1])
C0444921 (UMLS CUI [1,2])
C4055223 (UMLS CUI [2,1])
C0205412 (UMLS CUI [2,2])
Disease-Modifying Antirheumatic Drugs Background | Duration of therapy Dose Stable
Item
taking background dmards for a minimum of 3 months and at stable doses for at least 28 days
boolean
C0242708 (UMLS CUI [1,1])
C1706907 (UMLS CUI [1,2])
C0444921 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Item Group
C0680251 (UMLS CUI)
Bacterial Infection Serious
Item
serious bacterial infection in last 3 months
boolean
C0004623 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
Tuberculosis
Item
history of tb
boolean
C0041296 (UMLS CUI [1])
Malignant Neoplasms
Item
history of cancer within 5 years
boolean
C0006826 (UMLS CUI [1])
Bacterial Infection Latent Evidence of | Bacterial Infection Evidence of | Virus Disease Latent Evidence of | Virus Disease Evidence of
Item
evidence of latent or active bacterial or viral infection
boolean
C0004623 (UMLS CUI [1,1])
C0205275 (UMLS CUI [1,2])
C0332120 (UMLS CUI [1,3])
C0004623 (UMLS CUI [2,1])
C0332120 (UMLS CUI [2,2])
C0042769 (UMLS CUI [3,1])
C0205275 (UMLS CUI [3,2])
C0332120 (UMLS CUI [3,3])
C0042769 (UMLS CUI [4,1])
C0332120 (UMLS CUI [4,2])
intraarticular injection of corticosteroids
Item
intra-articular corticosteroids within 3 months
boolean
C2064783 (UMLS CUI [1])
Exposure to Attenuated Vaccines
Item
exposure to live vaccines
boolean
C0332157 (UMLS CUI [1,1])
C0042211 (UMLS CUI [1,2])
Exposure to abatacept | Exposure to BMS 188667
Item
exposure to ctla4ig or bms-188667
boolean
C0332157 (UMLS CUI [1,1])
C1619966 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C0378942 (UMLS CUI [2,2])
Apheresis Immunoadsorption Columns | mycophenolate mofetil | leflunomide | anakinra | Cyclosporine | Etanercept | adalimumab | infliximab | Azathioprine | Oral form medicinal gold | Parenteral form medicinal gold | Penicillamine | Calcineurin inhibitor | Cyclophosphamide | Alkylating Agents
Item
treatment with immunoadsorption column(s), mycophenolate mofetil, leflunomide, anakinra, cyclosporine, etanercept, adalimumab, infliximab, azathioprine, oral or parenteral gold, d-penacillamine, calcineurin inhibitors, cyclophosphamide or other alkylating agents
boolean
C0179100 (UMLS CUI [1])
C0209368 (UMLS CUI [2])
C0063041 (UMLS CUI [3])
C0245109 (UMLS CUI [4])
C0010592 (UMLS CUI [5])
C0717758 (UMLS CUI [6])
C1122087 (UMLS CUI [7])
C0666743 (UMLS CUI [8])
C0004482 (UMLS CUI [9])
C2585247 (UMLS CUI [10])
C2585314 (UMLS CUI [11])
C0030817 (UMLS CUI [12])
C1562036 (UMLS CUI [13])
C0010583 (UMLS CUI [14])
C0002073 (UMLS CUI [15])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial